Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1491-1500 Newer>

The Motley Fool October 26, 2004 Charly Travers	Sepracor's Tough Road to Profits Will insomnia drug Estorra take the company to the promised land?
The Motley Fool October 26, 2004 Charly Travers	Biotech's 5-Baggers: Part 2 Several hot drugs are generating smoking returns. If the goal for an investor is to aim for one of these five-baggers, then one option is to invest before the company passes through the inflection point.
The Motley Fool October 25, 2004 Tom Taulli	McKesson Gets Pain Relief Drug distributors would like to forget 2004. But this may mean bargains for investors.
Reactive Reports Issue 41 David Bradley	Chip Chops Time off Drug Discovery Process A next-generation optical screening platform can screen a vast number of compounds rapidly by passing wave after wave of compounds in solution over the surface of the biochip.
BusinessWeek November 1, 2004 Amy Barrett	This Pep Pill is Pushing Its Luck Half of Provigil prescriptions may be for "off-label" uses. Did its maker cross the line? But Cephalon is hardly the only drugmaker in the spotlight.
Entrepreneur November 2004 Julie Monahan	Club Meds Fed up with the high cost of prescription drugs, a group of 50 employers from the Fortune 500 are banding together to negotiate a better deal with pharmaceutical companies.
The Motley Fool October 22, 2004 W.D. Crotty	CNS's Whiff of Fresh Air The company's Breathe Right franchise is a real money machine. Net income of $0.24 a share beat analyst estimates by $0.05 and the top end of the company's guidance.
The Motley Fool October 22, 2004 Rich Duprey	Chiron Reports Profit, But So What? The flu vaccine debacle overshadows the company's profits and earnings.
The Motley Fool October 21, 2004 W.D. Crotty	One Value-Priced Biotech Giant Amgen is a growing cash machine selling at the market's multiple to earnings.
The Motley Fool October 21, 2004 Roger Nusbaum	Pictures of Lilly Eli Lilly's numbers get lost in the wake of Merck and Pfizer. While the market waits for drug stocks to recover, investors can collect Lilly's 2.5%, safe, dividend.
<Older 1491-1500 Newer> Return to current articles.